Oncothyreon promotes Diana Hausman to CMO
This article was originally published in Scrip
Dr Diana Hausman has been promoted to chief medical officer of Oncothyreon, a biotechnology company developing therapeutic oncology products. Dr Hausman joined Oncothyreon in August 2009 as vice-president of clinical development. She was previously employed at Zymogenetics as senior director of clinical research.